Journey Medical Corp
Close on Oct 19, 2026
- Market cap
- $142.14M
- P/E (TTM)
- –
- Dividend yield
- –
About Journey Medical
Pharmaceutical Preparations, SIC 2834
Journey Medical Corporation is a commercial-stage pharmaceutical company that acquires, develops, and commercializes prescription pharmaceutical treatments for dermatological conditions. The company markets a portfolio of prescription products targeting diseases such as rosacea, severe acne, primary axillary hyperhidrosis, fungal skin infections, and wound care, with major brands including Emrosi, Qbrexza, Accutane, Amzeeq, and Zilxi. Its primary customers are specialty pharmacies, independent wholesalers, and distributors, which subsequently supply medications to retail pharmacy chains, independent pharmacies, and managed care organizations.
The company generates substantially all of its product revenues within the United States, alongside supplying select products to international partners such as Cutia Therapeutics in the People's Republic of China. Its distribution network encompasses more than 600 specialty pharmacies and wholesalers nationwide, supported by an internal commercial workforce of 58 full-time employees. Journey Medical Corporation is headquartered in Scottsdale, Arizona.
Summary of the business section of Journey Medical's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Journey Medical Corp
- Founded
- 2014
- Headquarters
- Scottsdale, AZ
- Address
- 9237 E Via De Ventura Blvd., Suite 105 85258
- Phone
- (480) 434-6670
- Website
- jmcderm.com
- Employees
- 58, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Short Hills, New Jersey
Stock & identifiers
- Ticker
- DERM
- Exchange
- Nasdaq
- Shares outstanding
- 28M, Aug 11, 2026
- Public float
- $84.66M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1867066
- CUSIP
- 48115J109
- ISIN
- US48115J1097
- EIN
- 47-1879539
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Claude Maraoui | President & CEO, Director | 2,435,990 |
| Ramsey Alloush | Chief Operating Officer | 598,543 |
| Joseph Benesch | CFO | 261,371 |
| Miranda Jayne Toledano | Director | 168,618 |
| Justin Adam Smith | Director | 231,618 |
| Neil Herskowitz | Director | 168,618 |
| Michael Cooper Pearce | Director | 67,173 |
| Lindsay A. Rosenwald Md | Director | 397,616 |
Employees
Headcount reported in annual reports
“As of March 18, 2026, we had 58 employees, all of whom are full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 18, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 16, 2023 | Late filing | Notification of late filing |
| Nov 12, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |